Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly six months since my last Aquestive Therapeutics (NASDAQ: AQST ) article , where I discussed five areas of focus for the company in 2025, including Anaphylm's potential FDA approval. Since then, the ticker is down roughly 2%, but the c ...

WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Cent ...

Group 1 - The company has a strong academic foundation with an MBA in Finance and an MD, enhancing its expertise in the financial sector [1] - The firm specializes in income investing and biotech/pharma investing, with nearly a decade of experience in these areas [2] - The organization focuses on identifying both short-term catalyst-driven opportunities and long-term investment strategies in the biotech sector [3] Group 2 - Subscribers receive regular portfolio trade alerts and have access to an interactive chat feature, promoting engagement and addressing inquiries [4] - The company has published a best-selling book on biotech investing and offers an online course, showcasing its commitment to educating investors [4] - The firm provides custom biotech analysis upon request, ensuring tailored insights for its audience [3][4]

Aquestive Therapeutics (AQST) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Company Participants Brian Korb - Co-Founder & Managing DirectorDaniel Barber - CEO, President & DirectorErnie Toth - Chief Financial OfficerSherry Korczynski - Senior Vice President of Sales & MarketingCarl Kraus - Chief Medical OfficerJason Butler - Managing Director & Biotechnology Equity ResearchRaghuram Selvaraju - Managing Director, Healthcare Equity ResearchDenis Reznik - Senior Equity Research AssociateNelson Cox - Equity R ...

Aquestive Therapeutics (AQST) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Aquestive Therapeutics first quarter twenty twenty five earnings conference call. At this time, all participants are in a listen only mode. After the speakers' presentation, there'll be a question and answer session. Please be advised today's conference is being recorded. I would now like to turn the conference over to your host today, Brian Korb. Please go ahead. Spe ...

For the quarter ended March 2025, Aquestive Therapeutics (AQST) reported revenue of $8.72 million, down 27.6% over the same period last year. EPS came in at -$0.24, compared to -$0.17 in the year-ago quarter.The reported revenue represents a surprise of -28.14% over the Zacks Consensus Estimate of $12.14 million. With the consensus EPS estimate being -$0.17, the EPS surprise was -41.18%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations ...

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -41.18%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.14 per share when it actually produced a loss of $0.19, delivering a surprise of -35.71%.Over the last four ...

First Quarter 2025 Earnings Supplemental Materials September 2024 May 12, 2025 Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. ® Disclaimer Certain statements in this press release include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "pl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of Inco ...

Exhibit 99.1 Anaphylm™ (epinephrine) Sublingual Film Aquestive has completed the submission of its New Drug Application (NDA) for Anaphylm with the U.S. Food and Drug Administration (FDA). The NDA includes data from the full adult clinical program and the recently completed pediatric study. Topline results from the pediatric trial in patients aged 7 to 17 demonstrated a pharmacokinetic (PK) profile consistent with prior adult clinical data, supporting a proposed label aligned with the 0.3 mg epinephrine aut ...